dual gip and glp-1 receptor agonist GLP-1/GIP | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Science Behind GLP 1 GIP

Patients receiving semaglutide (0.5 or 1.0 mg) for 104 weeks demonstrated a significantly higher risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or required procedural treatment compared to those receiving placebo (HR, 1.76

Yao, Y., Xu, X

Bailey, C

Three diabetes incretin medications are now approved for pediatric use starting at age 10 (see cheat sheet), and two incretin-based weight management medications are approved for children aged 12 and older

This pathway facilitates the generation of NO, thereby contributing to the preservation of vascular health and endothelial function

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis